Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ipilimumab Data Impress, But Vaccine Control Could Complicate Review

Executive Summary

CHICAGO - The Phase III results for Bristol-Myers Squibb's ipilimumab represent a breakthrough in melanoma, stole the show at the 2010 American Society of Clinical Oncology annual meeting and are generally expected to presage the first approval of a CTLA-4 inhibitor and the first approval in the disease for more than a decade. But the unexpectedly lackluster performance of an experimental vaccine used with the trial drug and as a control has created some interesting clinical and regulatory plot twists
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS052325

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel